Fundraising FoxCatalyst Investments — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Omeza is an ocean biotechnology company developing marine-based regenerative wound-care products, including its FDA-cleared OCM wound matrix made from cold-water fish peptides, omega fatty acids, and plant-derived lipids, to treat chronic, hard-to-heal wounds such as diabetic foot ulcers and venous leg ulcers in adults.
BiotechHealthtechMedical DevicesSarasota, US
Cynthia Flowers(Executive Officer, Director)inRonald Gelbman(Director)Thomas Gardner(Executive Officer, Director)Joel Morganroth(Director)Robert Essner(Director)
BoardAG Lafley(Director)
Co-investorsFlorida Opportunity Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.